ADC THERAPEUTICS SA's ticker is ADCT and the CUSIP is H0036K147. A total of 42 filers reported holding ADC THERAPEUTICS SA in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $475,311 | -52.8% | 529,890 | +13.1% | 0.00% | – |
| Q2 2023 | $1,007,286 | -18.7% | 468,505 | -26.3% | 0.00% | – |
| Q1 2023 | $1,239,316 | -38.7% | 635,547 | +20.6% | 0.00% | – |
| Q4 2022 | $2,022,877 | -1.9% | 526,791 | +23.1% | 0.00% | – |
| Q3 2022 | $2,063,000 | -44.4% | 427,866 | -8.3% | 0.00% | – |
| Q2 2022 | $3,711,000 | -17.0% | 466,804 | +53.4% | 0.00% | – |
| Q1 2022 | $4,469,000 | -24.7% | 304,229 | +3.5% | 0.00% | – |
| Q4 2021 | $5,936,000 | -30.3% | 293,857 | -6.3% | 0.00% | – |
| Q3 2021 | $8,518,000 | +16.3% | 313,641 | +4.3% | 0.00% | – |
| Q2 2021 | $7,323,000 | +38.6% | 300,738 | +82.2% | 0.00% | – |
| Q4 2020 | $5,283,000 | -3.0% | 165,021 | 0.0% | 0.00% | – |
| Q3 2020 | $5,444,000 | -29.3% | 165,021 | +0.3% | 0.00% | – |
| Q2 2020 | $7,700,000 | – | 164,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vantage Consulting Group Inc | 1,186,215 | $4,555,066 | 2.69% |
| Blue Owl Capital Holdings LP | 733,568 | $2,816,901 | 1.20% |
| Redmile Group, LLC | 7,590,849 | $29,148,860 | 1.19% |
| AlphaCentric Advisors LLC | 297,500 | $1,142,400 | 1.13% |
| Prosight Management, LP | 463,310 | $1,779,110 | 0.97% |
| GCM Grosvenor Holdings, LLC | 735,471 | $2,824,209 | 0.72% |
| Indie Asset Partners, LLC | 93,839 | $360,342 | 0.40% |
| XTX Topco Ltd | 197,635 | $758,918 | 0.16% |
| Eventide Asset Management | 1,879,959 | $7,219,043 | 0.14% |
| Nantahala Capital Management | 243,290 | $934,234 | 0.06% |